Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine

TUESDAY, May 18, 2021 -- Individuals with inflammatory bowel disease who are treated with infliximab rather than vedolizumab have reduced immunogenicity to a single dose of BNT162b2 and ChAdOx1 nCoV-19 severe acute respiratory syndrome coronavirus 2...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news